IRIDEX Co. (NASDAQ:IRIX) Short Interest Update

IRIDEX Co. (NASDAQ:IRIX) was the recipient of a large decline in short interest in October. As of October 31st, there was short interest totalling 309,800 shares, a decline of 8.0% from the October 15th total of 336,800 shares. Based on an average daily trading volume, of 25,000 shares, the days-to-cover ratio is presently 12.4 days. Currently, 2.5% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of IRIDEX in a research note on Sunday. They set a “hold” rating on the stock.

IRIDEX Trading Up 4.1 %

IRIDEX stock opened at $1.76 on Tuesday. The stock has a market capitalization of $29.28 million, a PE ratio of -2.63 and a beta of 0.80. IRIDEX has a 12-month low of $1.27 and a 12-month high of $3.65. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 0.86. The firm has a 50 day simple moving average of $1.67 and a 200-day simple moving average of $2.01.

IRIDEX (NASDAQ:IRIX) last posted its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. The firm had revenue of $11.58 million during the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. During the same period last year, the company earned ($0.11) earnings per share.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.